EMERGENT BIOSOLUTIONS INC. Shareholders' Equity
EMERGENT BIOSOLUTIONS INC. (EBS) had Shareholders' Equity of $341.40 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $341.40M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $523.10M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $522.60M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $582.50M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $341.40M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $523.10M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $522.60M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $582.50M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $536.20M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $552.70M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $482.80M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $508.40M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $386.30M 10-Q · filed 2025-10-30 | |
| 2024-03-31 | $663.90M 10-Q · filed 2025-10-30 | |
| 2023-12-31 | $649.30M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $697.20M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $957.70M 10-Q · filed 2024-11-07 | $956.30M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $1.20B 10-Q · filed 2024-11-07 | $1.20B 10-Q · filed 2023-05-10 |
| 2022-12-31 | $1.39B 10-K · filed 2026-02-27 | $1.38B 10-K · filed 2023-03-01 |
| 2022-09-30 | $1.43B 10-Q · filed 2023-12-11 | $1.45B 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.51B 10-Q · filed 2023-12-11 | $1.51B 10-Q · filed 2022-08-02 |
| 2022-03-31 | $1.57B 10-Q · filed 2023-12-11 | $1.58B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $1.61B 10-K · filed 2025-03-04 | $1.62B 10-K · filed 2022-02-25 |
| 2021-09-30 | $1.52B 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.54B 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $1.52B 10-Q · filed 2022-08-02 | |
| 2020-12-31 | $1.45B 10-K · filed 2024-03-08 | $1.45B 10-K · filed 2021-02-19 |
| 2020-09-30 | $1.25B 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $1.20B 10-Q · filed 2021-11-05 | |
| 2020-03-31 | $1.07B 10-Q · filed 2021-07-30 | |
| 2019-12-31 | $1.09B 10-K/A · filed 2023-12-11 | $1.09B 10-K · filed 2020-02-25 |
| 2019-09-30 | $1.03B 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $988.90M 10-Q · filed 2020-11-06 | |
| 2019-03-31 | $987.30M 10-Q · filed 2020-07-31 | |
| 2018-12-31 | $1.01B 10-K · filed 2022-02-25 | |
| 2018-09-30 | $966.60M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $938.40M 10-Q · filed 2019-11-07 | $938.30M 10-Q · filed 2019-08-02 |
| 2018-03-31 | $881.30M 10-Q · filed 2019-08-02 | |
| 2017-12-31 | $912.30M 10-K · filed 2021-02-19 | |
| 2016-12-31 | $596.20M 10-K · filed 2020-02-25 | |
| 2014-12-31 | $553.20M 10-K · filed 2015-03-09 | |
| 2014-09-30 | $513.14M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $487.77M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $477.50M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $489.62M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $467.31M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $449.53M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $435.59M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $441.36M 10-K · filed 2014-03-10 | |
| 2012-09-30 | $427.04M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $419.69M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $409.59M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $414.25M 10-K · filed 2013-03-08 | |
| 2011-09-30 | $381.29M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $377.25M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $369.46M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |